Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026

Cullinan Therapeutics (Nasdaq: CGEM) announced that CEO Nadim Ahmed and CMO Jeffrey Jones, M.D., M.B.A., will take part in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 a.m. ET.

Rhea-AI Summary

Cullinan Therapeutics (Nasdaq: CGEM) announced that CEO Nadim Ahmed and CMO Jeffrey Jones, M.D., M.B.A., will take part in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 11:00 a.m. ET.

A live webcast will be available via the company’s investor relations Events and Presentations page at https://investors.cullinantherapeutics.com/events.

Argus Feb 5 session

-3.89% close to close Open Argus

Details

News Market Reaction – CGEM

On Feb 5, the day this news came out, CGEM closed 3.89% below the previous close.

Data tracked by StockTitan Argus for the Feb 5 session.

Market Context

This announcement adds another investor-focused event to Cullinan Therapeutics’ calendar, highlighti...

Analysis

This announcement adds another investor-focused event to Cullinan Therapeutics’ calendar, highlighting continued engagement through a Guggenheim biotech summit fireside chat on February 12, 2026. In recent months, the company communicated substantial clinical and regulatory progress, including CLN-049 data and a rolling NDA for zipalertinib, alongside a reported $439.0M cash position and runway into 2029. Observers may watch for any incremental commentary emerging from the event.

Key Figures

Summit date: February 12, 2026 Event time: 11:00 a.m. ET

Summit date

February 12, 2026

Guggenheim Emerging Outlook: Biotech Summit 2026 fireside chat

Event time

11:00 a.m. ET

Scheduled time for Guggenheim fireside chat

Historical Context

5 past events · Latest: Jan 08

5 events

1. Jan 08

   Corporate update

   24h Move

   +1.8%

   Outlined 2026 milestones and highlighted $439.0M cash runway into 2029.

2. Dec 08

   Clinical data update

   24h Move

   +17.5%

   Updated Phase 1 CLN-049 AML data with encouraging response rates and safety.

3. Dec 01

   Regulatory designation

   24h Move

   -5.5%

   FDA Fast Track designation for CLN-049 in R/R AML and planned ASH presentation.

4. Nov 20

   Regulatory filing

   24h Move

   +3.2%

   Initiated rolling NDA for zipalertinib in EGFR ex20ins NSCLC with prior positive data.

5. Nov 10

   Conference participation

   24h Move

   +3.5%

   Announced participation in investor conferences and ASH analyst/investor event.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 11:00 a.m. ET.

A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

Contacts:

Investors
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com

Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Cullinan Therapeutics (CGEM) present at the Guggenheim Biotech Summit 2026?

Cullinan will present on February 12, 2026 at 11:00 a.m. ET. According to the company, CEO Nadim Ahmed and CMO Jeffrey Jones will participate in a fireside chat and the event is part of the Guggenheim Emerging Outlook: Biotech Summit 2026.

Who from Cullinan Therapeutics (CGEM) will speak at the February 12, 2026 fireside chat?

CEO Nadim Ahmed and CMO Jeffrey Jones, M.D., M.B.A., will speak. According to the company, both executives will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 11:00 a.m. ET.

How can investors watch Cullinan Therapeutics' (CGEM) fireside chat webcast on February 12, 2026?

The webcast will be available on the company’s investor relations Events and Presentations page. According to the company, viewers can access the live webcast at https://investors.cullinantherapeutics.com/events during or after the February 12, 2026 presentation.

What topics will Cullinan Therapeutics (CGEM) likely cover in the Guggenheim Biotech Summit fireside chat?

The announcement states executives will participate in a fireside chat but does not list topics. According to the company, the session will feature CEO Nadim Ahmed and CMO Jeffrey Jones, suggesting discussion of corporate strategy and clinical-stage programs may be expected.

Is the Cullinan Therapeutics (CGEM) fireside chat at Guggenheim open to the public or investors only?

The company lists a webcast on its investor relations site, implying broad online access. According to the company, the fireside chat will be webcast via the Events and Presentations page, enabling public and investor viewing without specifying registration requirements.

Will Cullinan Therapeutics (CGEM) provide a replay of the February 12, 2026 fireside chat?

A webcast will be available on the investor relations Events and Presentations page, which typically hosts replays. According to the company, the webcast will be posted at https://investors.cullinantherapeutics.com/events for viewing after the live session.